Researcher challenges universal use of AREDS2 formulation

SAN DIEGO — Optimal treatment for 65% of AREDS 2 study patients is something other than the AREDS formulation, Carl C. Awh, MD, told colleagues at the American Society of Retina Specialists annual meeting.In an outcomes analysis of patients and AREDS data, Awh said patients with high complement factor H (CFH) risk and no ARMS2 risk treated with the AREDS formulation had a 135% increased AMD progression compared with those treated with placebo — that is, 13% of patients in the study.